Skip to content
IonOpticks commences construction of purpose-built facility to drive future growth and innovation.


FOR IMMEDIATE RELEASE

Tuesday, July 2, 2024 – MELBOURNE: IonOpticks is entering an exciting new phase of expansion, having outgrown its existing facilities in recent months. To accommodate this progress, the company has taken on a new lease and appointed builder David Murphy of Challenge Group to construct a purpose-built facility in Melbourne, designed thoughtfully and responsibly by JMA Architects

Four people standing in a row in front of a construction site as IonOpticks builds new facility in Melbourne. From left to right, Property and Facilities Project Manager, David Sinden; Managing Director, Xavier Perronnet; Head of Brand, Michael Sinden; Managing Director, Challenge Group, David Murphy.

L to R: Property and Facilities Project Manager, David Sinden; Chief Executive Officer Xavier Perronnet; Chief Brand Officer, Michael Sinden; Managing Director, Challenge Group, David Murphy.

The stunning art-deco premises in Melbourne’s inner east will see the fit-out span two floors and house IonOpticks’ bespoke manufacturing facility, R&D laboratory, and corporate headquarters. The contemporary and sustainable design reflects the company’s commitment to innovation and excellence, ensuring that this new home will support its ambitions for years to come. IonOpticks’ Chief Brand Officer, Michael Sinden said of the plans:

Three people standing around talking on a construction site as IonOpticks builds new facility in Melbourne. From left to right, David Murphy, Xavier Perronnet and David Sinden.

A vital step in strengthening the company’s market position, the project advances ambitious development plans and provides another solid foundation for IonOpticks towards its goal: to enable transformative human health advancements by democratising elite-level chromatographic tools for labs worldwide, as Chief Executive Officer Xavier Perronnet explains: 

By investing in this new infrastructure, the company is well-positioned to meet the growing demand for its products and services, ensuring that it continues to lead in the field of chromatography. As plans progress, IonOpticks looks forward to the opportunities this new facility will bring and the impact it will have on its ability to innovate and grow. More updates to follow as the project develops.

—ENDS—

MEDIA CONTACT

Michael Sinden, CBO, IonOpticks via [email protected]

About IonOpticks
IonOpticks produces high-performance chromatography solutions for the global research community enhancing mass spectrometry (LC-MS) and high-end proteomics research.

Their solutions enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples. These advancements are valuable for a broad range of applications within the field of biological and medical research including drug discovery, phosphoproteomics and shotgun proteomics. https://ionopticks.com/
Share:

Related publications & news

PRESS RELEASE Melbourne, February 24 2025: IonOpticks, a world-leading prov...
FOR IMMEDIATE RELEASE Melbourne | Zurich, 05 December 2024: Today, IonOptic...
In a field where precision and efficiency are paramount, IonOpticks is givi...
FOR IMMEDIATE RELEASE MELBOURNE AUSTRALIA: IonOpticks, a leading global pro...
At the core of groundbreaking scientific discoveries are people who are dri...
IonOpticks, a leading global producer of high-performance chromatography co...
Melbourne, April 22 2024: IonOpticks has proudly been awarded a Silver Winn...
Previous
Next